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Preinvasive Lesions of the Bronchus
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Abstract: Preinvasive lesions are considered the precursors of
squamous cell carcinoma of the bronchus. Treatment at the prein-
vasive stage, before the potential for metastasis, may improve
survival from squamous cell carcinoma. An understanding of the
natural history and outcome of preinvasive lesions is essential for
the accurate interpretation studies of their treatment, and decisions
regarding the management of individual lesions. The natural history
of preinvasive lesions has only been reported in a small number of
highly selected patients and uses different inclusion criteria, treat-
ment criteria. and time-periods of follow-up, making it difficult to
draw definitive conclusions. High-grade preinvasive lesions carry a
risk of progression to carcinoma but most patients have multiple
lesions and a significant probability of developing new lesions over
time. Distinguishing lesions with malignant potential, the targets for
therapy, from those that will regress or remain indolent is difficult.
The American College of Chest Physicians guidelines recommend
bronchoscopic follow-up of severe dysplasia and carcinoma-in situ.
This review of the evidence regarding the natural history and
outcome of preinvasive lesions supports this view, but also shows
that further studies in individuals at risk for lung cancer are neces-
sary before guidelines for the management of preinvasive lesions
can be developed.
Key Words: Preinvasive lesions, Bronchial carcinoma, Natural
history.
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Preinvasive lesions are defined as “a precursor lesion ofsquamous cell carcinoma arising in the bronchial epithe-
lium. Squamous dysplasia and carcinoma-in situ are a con-
tinuum of recognisable histologic changes in the large air-
ways. They can occur as single or multifocal lesions
throughout the tracheobronchial tree. Dysplasia or carcino-
ma-in situ may exist as an isolated finding or as a bronchial
surface lesion accompanying invasive carcinoma.”1 They are
small, and difficult to visualize using conventional white light
bronchoscopy.2 Autofluorescence bronchoscopy has been de-
veloped specifically to detect preinvasive lesions, and has
improved the sensitivity of lesion detection by 1.5 to 6
fold.3–5 The ability to detect lesions, particularly those of
higher-grade, has enabled the study of preinvasive lesions as
a means of early identification and treatment of squamous cell
carcinoma of the bronchus.
The basement membrane is intact6 in preinvasive le-
sions, and there is no possibility of metastatic spread, which
is in contrast to squamous cell carcinoma where there is the
potential for metastasis as soon as invasion occurs. There is
some evidence that a 90% 5-year survival might be achieved
by treating lesions at the preinvasive stage.7,8 Consequently,
preinvasive lesions are thought good candidates for therapy,
with the aspiration that their treatment will improve long-
term survival from carcinoma of the bronchus. There is a
discrepancy between the prevalence of preinvasive lesions9
and the incidence of lung cancer,10 which suggests that not all
lesions inevitably develop into carcinoma. This raises ques-
tions regarding their treatment, as lesions that are not at risk
for malignancy should not require intervention. To determine
which lesions are at risk, a knowledge of the natural history
of preinvasive lesions is necessary.
The entire bronchial epithelium is exposed to carcino-
gen from cigarette smoke, and malignancy can develop in any
location within that exposed epithelium.9,11 It has been sug-
gested that the only way to treat this “field carcinogenesis” is
to use a systemic chemopreventative agent. Although one
trial showed some benefit,12 others have been less success-
ful.13–15 As our understanding of the biology of preinvasive
lesions and the genetic switches that control their behavior
increases, it is anticipated that specific chemopreventive
agents will be discovered. However, the outcomes of studies
of chemopreventative agents cannot be accurately assessed
until a reliable predictive model for the long-term progress of
individual preinvasive lesions is available. An understanding
of the natural history of preinvasive lesions is central to both
the interpretation of studies of treatment, and also decisions
regarding the management of manifest lesions.
Prevalence of Preinvasive Lesions
The seminal study by Auerbach et al.9 in the 1950s
showed that preinvasive lesions were a frequent finding in the
bronchial epithelium of smokers and patients with lung can-
cer. Only male patients were included, and the study was
performed on a very different population from the patients of
today. There was no “dysplasia” category in their classifica-
tion of lesions, and carcinoma-in situ was defined as “all
bronchial epithelial lesions composed entirely of atypical
cells and lacking cilia.” The authors accepted that there were
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differences between the lesions categorised as “carcinoma-in
situ” but could not differentiate the lesions further due to a
lack of sensitivity in their techniques. Furthermore, the nature
of cigarettes and smoking has changed over the last 50
years.16 For these reasons the prevalence data for preinvasive
lesions from 50 years ago may not be applied easily to
today’s patients.
The prevalence of preinvasive lesions was addressed in
a more recent study by Paris et al.17 In 241 patients at high
risk for lung cancer (as defined by the International Associ-
ation for the Study of Lung Cancer criteria) the prevalence of
high-grade preinvasive lesions was 9%. The prevalence was
higher in current (12%) than former smokers (4%). The
severity of dysplasia observed within the bronchial tree was
related to the extent of tobacco exposure. There was a clear
association between the presence of high-grade preinvasive
lesions and previous carcinoma of the bronchus, a history of
head and neck carcinoma (odds ratio 4.0 based on 15 pa-
tients) and occupational exposure to asbestos or other carcin-
ogens. The risk of having a high-grade preinvasive lesion
ranged from 0.2 to 90.4% and was related to the number of
risk factors for carcinoma within the individual patient. A
multicenter randomized study by Ha¨ußinger et al.18 using a
different autofluorescence system stratified 1173 patients by
their risk factors. The highest prevalence of preinvasive
lesions was in patients with abnormal sputum cytology but
normal chest radiology (11.1%). Patients with previously
resected carcinomas had a prevalence of 6.7% and those with
radiologic or clinical suspicion of lung cancer 4.6%. There
were no preinvasive lesions found in those with Chronic
Obstructive Pulmonary Disease or occupational exposure to
carcinogen alone.
Further data are available from the chemoprevention
studies of Lam and colleagues where volunteer smokers
underwent autofluorescence bronchoscopy. The prevalence
of carcinoma-in situ was 1.8%, severe dysplasia 6.5%, mod-
erate dysplasia 14%, and mild dysplasia 40%.19 Males
seemed to have a higher prevalence of preinvasive lesions,
high-grade lesions occurring in 31% of males but only 14%
of females.19 The overall prevalence and number of lesions
per patient were lower in females even after adjustment for
smoking. The reasons for this are not clear but may be related
to sex-related differences in the susceptibility of the epithe-
lium to the toxic effects of cigarette smoke.
Implications of the Presence of Preinvasive
Lesions
The presence of preinvasive lesions of the bronchus
signifies an increased likelihood of development of carci-
noma of the bronchus. Loewen et al.20 recently described a
group of 169 patients from the USA undergoing surveillance
using computed tomography scanning and autofluorescence
bronchoscopy. Of the patient group, 66% had preinvasive
lesions of squamous metaplasia or worse and 7% developed
a lung cancer in the 3 to 16 month follow-up period, over half
of which were adenocarcinomas. A similar group of 46
patients, reported by Pasic et al.,21 were followed up using
autofluorescence bronchoscopy 4 to 6 monthly for a median
of 50 months. The number of preinvasive lesions found
within the airways was related to the patient’s probability of
carcinoma development. In contrast to the USA study above,
24% of this Dutch group of patients developed squamous cell
carcinoma; no adenocarcinomas were found. The relationship
between the individual lesions followed and the development
of carcinoma was not discussed. A 4 year study in Italy22
showed that 10 of 22 patients with dysplasia developed a
carcinoma, 7 of which were squamous cell, during follow-up.
The grade of dysplasia at baseline was related to the proba-
bility that a carcinoma would occur. There was no broncho-
scopic follow-up, and so once again the relationship between
individual lesions and the development of carcinoma could
not be determined. Additional information is provided by the
study by Sin et al.23 from Canada, where a raised serum
C-reactive protein was associated with the histologic progres-
sion of dysplasia or the development of new lesions in 50%
of the study patients. These data suggest that in patients at
high-risk for lung cancer, preinvasive lesions of high grade
are prevalent. The risk of development of carcinoma of the
bronchus, particularly squamous cell, is related to their num-
ber and severity.
Natural History of Preinvasive Lesions
The literature on the subject has accumulated over 50
years and is difficult to interpret. The criteria for the diagnosis
and classification of preinvasive lesions has changed
twice1,6,9,24 which makes the analysis of older studies prob-
lematic. The possibility that an individual lesion may
progress to an invasive carcinoma has prompted some groups
to take the view that all carcinoma-in situ should be treated.25
Thus in many studies carcinoma-in situ and invasive carci-
noma were joint end-points, which compromises evaluation
of the natural history of high-grade lesions.26,27 In most
studies, higher grade lesions have been followed up for only
very short periods of time, typically less than 6 months, and
usually not as far as the development of invasive malignancy.25
The lesions were then treated, which invalidates the follow-up data.
Despite the 2004 World Health Organization guide-
lines,1 the differentiation between severe dysplasia and car-
cinoma-in situ, particularly in biopsy specimens, can be
difficult. It is interesting to note that the agreement between
the two observers for the reporting of the histopathology has
not been stated in any of the studies, nor was the quality of the
biopsies assessed. This is despite known difficulties with the
subdivision between mild and moderate dysplasia, between
severe dysplasia and carcinoma-in situ, and also the effect of
the quality and structural integrity of the biopsy on the
interpretability of the histologic features.28 Bronchoscopic
biopsy and specimen processing is known to compromise the
histologic appearance of some specimens. The interpretation
of studies of the natural history of preinvasive lesions is
critically dependent on accurate histology, particularly if
differentiation is to be made between carcinoma-in situ and
severe dysplasia. Assessment of interobserver agreement and
the quality of the biopsies presented should be an important
first step in the analysis of preinvasive lesion histologic
follow-up data.
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All of the studies of the natural history of preinvasive
lesions have used biopsy and histopathology to determine the
histologic grade of the lesions under follow-up. However, bi-
opsy involves disruption and removal of a proportion of the
lesion. The effect of this disruption and the impact on the natural
history of the lesion under investigation is not known. Addition-
ally, preinvasive lesions are often small,2 and may be completely
removed during biopsy.25 This suggests that the results of
previous studies of the natural history of preinvasive lesions may
have been compromised by biopsy. The effect of biopsy will not
be known until accurate and reproducible methods of lesion
classification using noninvasive means are developed.
TABLE 1. Studies of Follow-Up of Preinvasive Lesions
Study
Selection
Criteria
Patients
(n)
Male
(%)
Lesions
(no.)
Follow-up
(mo)
Lesion Types
Included
Lesions Types
Excluded Comments
Lam 200112 High-risk 101 61 248 6 Up to severe
dysplasia
CIS and carcinoma Chemoprevention
study
Bota 200125 High-risk 104 96 416 3–24 Up to SD CIS treated
Jeanmart 200327 Ex-smokers 48 94 80 18–36 Up to SD CIS and carcinoma
end-points
Breuer 200526 Smokers 52 85 134 11–21 Up to SD CIS and carcinoma
end-points
Hoshino 200429 Detected lesions 50 98 99 6–17 Up to SD None
Moro-Sibolot 200430 Detected lesions 27 89 31 25 CIS and SD LGL and
carcinoma
Lamy 200232 Detected lesions 37 NA 29 19–28 All No SD/CIS
reported
Methylation status
and outcome
Sozzi 200231 Detected lesions 2 100 20 48 All CIS treated Case study two
patients
Keith 200042 ASD only 11 NA 20 12 ASD All others Part of larger
histology study
George 200733 High risk 22 86 36 12–85 All None 9 patients previous
cancers
Lam 200212 High risk 91 61 245 6 All None Chemoprevention
study
Lam 200414 High risk 112 73 403 6 All None Chemoprevention
study
Studies Performed Using Pre-1999 WHO Criteria for Pre-invasive Lesions
Satoh 199734 SD and MiD
only
3 100 4 7–72 3 SD and 1
MiD
None Lesion follow-up
case study
Venmans 200036 CIS only 9 78 13 6 mo CIS  detected
in follow-up
All others PDT treatment
study
Thiberville 199535 High-risk 6 92 11 48 All Some CIS treated Molecular changes
study
Studies in Which Lesions Were Treated
Deygas 200140 CIS only 35 97 41 1–12 CIS All others Study of
cryotherapy
Studies of Resection Margin CIS
Pasic 200543 CIS only 11 82 11 11–89 CIS resection
margin
All others Resection margin
lesions only
Studies in Which Patient Outcome Determined (no individual lesion data)
Study Selection Criteria Patients (no.) Male (%) Follow-up (mo) Outcome Purpose of Study
Sin 200623 “Dysplasia” 65 75 6 50% progression
at 6 mo
Relationship outcome
to CRP
Ponticiello 200022 High-risk with dysplasia 22 69 48 10/22 carcinoma Relationship outcome
to grade of
dysplasia and p53
Pasic 200321 High-risk 46 85 12–80 11/46 carcinoma Retrospective.
Relationship number
of lesions to
outcome
High-risk is as defined by the IASLC criteria.
MiD, Mild dysplasia; MoD, Moderate dysplasia; SD, Severe dysplasia; CIS, Carcinoma-in-situ; ASD, Angiogenic squamous dysplasia; LGL, Low-grade lesion; PDT,
Photodynamic therapy; CRP, C-reactive protein; IASLC, International Association for the Study of Lung Cancer.
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The studies in which follow-up data on preinvasive
lesions can be found are listed in Table 1. Given the difficulty
in detecting preinvasive lesions,2 and their relatively low
frequency in the at-risk population,18 it is not surprising that
the majority of studies have included patients in whom
preinvasive lesions have already been identified. Most have
followed individual lesions, but some have followed the
whole patient, reporting outcome in terms of the observed
carcinoma, regardless of it’s location or cell type. There is
heterogeneity between the groups of patients included, the
specific types of lesion followed, the end-points of the studies
and the criteria for intervention for preinvasive lesions.
The largest study, that of Bota et al.,25 followed carci-
noma-in situ for only 3 months before endobronchial therapy.
No further posttreatment data are given, and the efficacy of
the treatments applied are not evaluated. Severe dysplasia
was followed up, and found to regress in a significant pro-
portion of patients. Only the ultimate outcome of an individ-
ual lesion was reported, limited by the length of the study,
and not the specific histologic or bronchoscopic features as
they evolved over time. Jeanmart et al.27 reported the out-
come of individual lesions over time. As both carcinoma-in
situ and invasive carcinoma were end-points the outcome of
severe dysplasia and carcinoma-in situ are difficult to evalu-
ate with certainty. The study by Breuer et al.26 had similar
issues, with the definition of “progression” of a high-grade
lesion including lesions that had remained stable for 3
months, or progression from severe dysplasia to carcinoma-in
situ. Only 11 lesions of high-grade were identified in the
study by Hoshino et al.29 and no lesions of carcinoma-in situ,
while studies by Moro-Sibolot et al.,30 Sozzi et al.,31 and
Lamy et al.32 contribute very few high-grade lesions to the
literature. George et al.33 reported 22 carefully characterized
patients followed for a median of 23 months. Although this
group was highly selected, the results were not compromised
by treatment to lesions. The lesions were grouped into “high-
grade” and “low-grade” categories to minimize the risk of
observer error in the histopathological reporting of bronchial
biopsies. The placebo arms of the chemoprevention studies of
Lam et al. provide valuable information, although follow-up
was for only 6 months and there were very few high-grade
lesions.14,15
It is difficult to interpret the studies of Satoh et al.,34
Thiberville et al.,35 and Venmans et al.36 alongside the more
recent studies as the lesions were classified using the 1981
World Health Organization criteria.24 In the study by Ven-
mans et al.36 in particular, all the carcinoma-in situ was
treated, which compromised the results. Satoh et al.34 fol-
lowed 4 lesions in 3 patients, all of which developed into
invasive carcinoma in up to 6 years. It is conspicuous that the
high grade lesions progressed more rapidly than the low-
grade lesion. The study by Thiberville et al.35 followed the
histologic and molecular progression of a series of preinva-
sive lesions, some of which were treated and some of which
were not. Four lesions are shown with their detailed histo-
logic follow-up data in the study by Breuer et al.,26 but
without timescales. These two studies also demonstrate that
there is some biopsy to biopsy variation of the histopatho-
logical diagnosis of lesions under follow-up.
Tables 2, 3 show the outcome of preinvasive lesions
from the literature. When the data from all the studies are
combined it is noted that preinvasive lesions may progress to
invasive squamous cell carcinoma, and the risk is much
higher for high-grade lesions than low-grade lesions. The
probability of progression seems higher for carcinoma-in situ
than severe dysplasia, but this is based on the analysis of 49
carcinoma-in situ lesions. It is not clear whether carcinoma-in
situ had indeed progressed to invasive carcinoma or persisted
as carcinoma-in situ in many of these lesions which makes
interpretation of the data difficult. A significant proportion of
carcinoma-in situ and severe dysplasia lesions regress to-
wards normal epithelium. It has been suggested that severe
dysplasia is more likely to regress than carcinoma-in situ, but
the protocol of the study in question treated carcinoma-in situ
if it persisted at 3 months which invalidates the conclusions
drawn.25 It is observed that as many carcinoma-in situ lesions
remain stable as progress to invasive carcinoma or regress
towards normal, suggesting that the length of follow-up has
been inadequate for some of these lesions. Combining carci-
noma-in situ and severe dysplasia together into a “high-
grade” lesion category shows an equal rate of progression and
regression. Low-grade lesions have a comparatively low risk
of progression and are most likely to regress to normal or
remain stable.
These data are based on 165 high-grade lesions in the
literature. It is questionable, given the low numbers of lesions
followed-up and the heterogeneity of inclusion criteria and
reporting of outcomes, whether any firm conclusions regard-
ing the clinical management of high-grade preinvasive le-
sions can be drawn. There are no clinical features that predict
the outcome of a manifest lesion. In this context, it would be
important to balance the risk of progression against the
efficacy of treatment, and the risk of significant disease
elsewhere in the bronchial tree.
All of this information must be interpreted in the light
of the changing histology of lung cancer worldwide. The
incidence of adenocarcinoma is increasing in some countries,
but squamous cell carcinoma remains the most frequent
histologic type in others.37,38 In one study, preinvasive lesions
were associated with the presence of peripheral nodules
within the lung.20 It is possible that the relevance of prein-
vasive lesions in terms of the risk of carcinoma development
may be changing. Alternatively, preinvasive lesions could
simply be a marker of cigarette exposure sufficient to induce
carcinogenesis but further detailed study is required.
Endobronchial Therapy and Preinvasive
Lesions
It has been suggested that endobronchial therapies may
be effective in treating high-grade lesions while sparing lung
and therefore lung function.39,40 Review of studies in which
lesions were treated and individual lesion follow-up data are
given (Table 3) shows that over one third of treated carcino-
ma-in situ progresses to invasive carcinoma, regardless of the
treatment modality used (although the most frequently used is
Photodynamic therapy). Interestingly, the proportion of le-
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sions progressing is similar to that of untreated carcinoma-in
situ. The numbers of lesions of severe dysplasia treated are
too small to draw valid conclusions. Low-grade lesions ap-
pear to derive no benefit from endobronchial therapy, with
the results of post-treatment follow-up almost identical to that
of untreated lesions. In addition, there is an observed inci-
dence (up to 37%) of the development of carcinoma else-
where in the lungs from 3 studies.27,33,40 For example, George
et al.33 showed a similar incidence of developing distant
carcinoma to that of carcinoma within the high-grade prein-
vasive lesion of interest. These data suggest that local endo-
bronchial treatment may be inadequate for the treatment of
carcinoma-in situ, may not prevent progression to invasive
carcinoma and cannot prevent distant carcinoma, although
these conclusions are based on a small number of treated
lesions. To date the only known effective therapy is surgery,
which can only be performed a limited number of times,
carries a significant morbidity, and may preclude curative
treatment should a carcinoma arise elsewhere. This approach
cannot be justified for an individual lesion when the risk of
malignant transformation is not known. The caveat is that,
these data were obtained before the widespread use of
endobronchial ultrasound and optical coherence tomogra-
phy. It is impossible to determine whether the treated
lesions in the various studies were genuinely carcinoma-in
situ or occult carcinoma, and whether the treated depth was
adequate. Studies of endobronchial therapy guided by
these newer techniques are necessary to re-establish their
efficacy.
In Summary
The natural history or progress of preinvasive lesions of
the bronchial epithelium over time has only been reported in
a small number of highly selected patients. Such studies offer
a short-term window onto the changing and evolving envi-
ronment of the bronchial mucosa. The literature regarding the
natural history of preinvasive lesions uses different inclusion
criteria, treatment criteria and time-periods of follow-up,
making it difficult to draw definitive conclusions using the
available data in this context. Bronchial carcinogenesis is a
long-term process which may take several years to develop,
and may occur at any time-point and any location within the
bronchial tree. There is no doubt that high-grade preinvasive
lesions carry a risk of progression to carcinoma but most
patients have multiple lesions and a significant probability of
developing new lesions over time. Distinguishing lesions
with malignant potential, the targets for therapy, from those
that will regress or remain indolent is difficult. The American
College of Chest Physicians guidelines41 recommend bron-
choscopic follow-up of severe dysplasia and carcinoma-in
situ. Review of the evidence supports this view, but also
shows that further studies of the natural history of preinvasive
lesions in individuals at risk for lung cancer are necessary
before guidelines for the management of preinvasive lesions
can be developed.
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